Enveda Secures $311M to Expand Nature‑Derived AI Drug Trials
TechCrunch1 min read90 words
Enveda has secured $311 million in new funding, a round that values the AI‑biotech company at $2 billion. The investment is aimed at accelerating the development of nature‑derived drugs that leverage artificial intelligence.
The company is currently testing compounds that treat skin conditions and that help preserve weight loss after patients discontinue GLP‑1 therapies. These trials represent the next step in Enveda’s pipeline of AI‑driven therapeutics.
Enveda’s $311 million round values the firm at $2 billion and it is testing drugs for skin conditions and weight‑loss preservation after GLP‑1 cessation.
Read the original at TechCrunch
🤖 AI-generated content — This article was automatically summarised from public RSS feeds by AutoBrief. Verify important information with the original source.